Quantum Genomics

📍 Paris, France🗓 Founded 2006👥 10 employees💰 Last funded Jun 2022
Pharmaceutical Manufacturing🌐 quantum-genomics.com
Website LinkedIn
The objective of Quantum Genomics is to become a leading actor in the treatment of cardio-vascular diseases through the development of a new therapeutic class: BAPAIs for BrainAminopeptidase A Inhibitors. We wish to develop and provide effective and well tolerated therapeutic treatments for controlling high blood pressure and to for preventing related cardio-vascular risks such as heart failure. High blood pressure remains a major public health concern. Quantum Genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the inhibition of brain Aminopeptidase A. The mid-term strategic objective of the company is to sign partnership agreements with major pharmaceutical companies which will take over and bring the products from the BAPAI technology to the market.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2006
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Quantum Genomics?
Quantum Genomics has 1 investors on record on gritt.io.
When did Quantum Genomics last raise funding?
The most recent investment in Quantum Genomics recorded on gritt.io was in June 2022.
When was Quantum Genomics founded?
Quantum Genomics was founded in 2006.
What industry is Quantum Genomics in?
Quantum Genomics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Quantum Genomics based?
Quantum Genomics is headquartered in Paris, France.